Ossianix

Ossianix is a private biotech leveraging a unique shark-derived VNAR antibody platform to overcome the significant challenge of delivering biologics across the blood-brain barrier. Its lead asset, the TXP1 Brain Shuttle, targets the transferrin receptor 1 (TfR1) to facilitate receptor-mediated transcytosis, demonstrating >40-fold enhanced brain delivery in primates with favorable specificity and pharmacokinetics. The company, founded by industry veterans and backed by strategic investors, is positioned to enable a new generation of CNS therapies through partnerships and internal pipeline development, though it faces competition and the inherent risks of pioneering a novel delivery modality.

Proprietary TXP1 Brain Shuttle platform based on a deimmunized shark VNAR (single-domain antibody) scaffold engineered to target transferrin receptor 1 (TfR1) for receptor-mediated transcytosis across the blood-brain barrier.

Ossianix operates in the competitive field of BBB modulation, facing rivals like Denali Therapeutics (with its Transport Vehicle platform), Roche, and others developing anti-TfR, anti-insulin receptor, and peptide-based shuttles. Differentiation hinges on the unique properties of the VNAR scaffold (size, stability) and the specific binding kinetics of its TXP1 candidate.